Semaglutide vs Tirzepatide: The Honest 2026 Comparison
Both are peptides. Both are FDA-approved. Both are everywhere. But semaglutide and tirzepatide aren’t the same drug — and the difference is bigger than the marketing suggests. Here’s the honest comparison.
The short answer
Tirzepatide hits two gut-hormone receptors (GIP and GLP-1); semaglutide hits one (GLP-1). In head-to-head-style trial data, tirzepatide produces more average weight loss (~20–22% vs ~15%), which is why many clinicians now reach for it first. But “more” isn’t automatically “right for you” — tolerance, cost, and access all matter. This is a conversation for a licensed provider, not a checkout button.
Side by side
| Semaglutide | Tirzepatide | |
|---|---|---|
| Brand names | Wegovy, Ozempic | Zepbound, Mounjaro |
| Mechanism | GLP-1 agonist | GLP-1 + GIP (dual) |
| Avg. weight loss in trials | ~15% | ~20–22% |
| Formats (2026) | Injection + oral | Injection |
Both are true peptides — engineered to mimic hormones your gut already makes. If that surprises you, start with Are GLP-1s actually peptides?.
What the trials actually show
Semaglutide’s STEP program and tirzepatide’s SURMOUNT program are the headline evidence. The numbers above are trial averages — individual results vary widely, and both were studied alongside diet and lifestyle changes, not as standalone fixes. Neither is a shortcut that removes the rest of the work.
Side effects, honestly
The common ones overlap: nausea, GI upset, and reduced appetite, usually heaviest when starting or increasing. Most are managed by how a provider titrates the dose — which is exactly why these are prescription drugs and not something to self-manage.
Cost and access in 2026
Both are typically cash-pay for weight management unless a plan covers them. Telehealth has made access simpler, and 2026 brought oral semaglutide to market, expanding options beyond injections. For how the prescribing path actually works, see How to get peptides prescribed, and check current regulatory status on the legal-status tracker.
So which one?
There’s no universal winner. Higher average weight loss (tirzepatide) has to be weighed against tolerance, format preference, cost, and availability — and against your actual health picture. Bring this comparison to a licensed provider and decide together.
Sources
- STEP trials (semaglutide) and SURMOUNT trials (tirzepatide)
- FDA approval records: Wegovy, Ozempic, Zepbound, Mounjaro
- 2026 oral semaglutide launch coverage
Educational content only — not medical advice. GLP-1 medications are prescription drugs; a licensed provider should determine what’s appropriate for you.